News for Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 10, Richard Law CFA from Goldman Sachs initiated coverage of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) with a Hold rating and a $36 price target. The analyst told investors that Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) near-term value […]

Crinetics Pharmaceuticals (CRNX) has announced that it will present new findings from its clinical development program for PALSONIFY, an investigational oral tr

Summary Crinetics Pharmaceuticals Inc (CRNX) has released new data from its clinical development program for PALSONIFYâ„¢ (paltusotine), an investigational oral

Summary Crinetics Pharmaceuticals Inc (CRNX) announced on July 13, 2025, the presentation of new data from its clinical development program for PALSONIFYâ„¢ (pa

Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label extensions of PATHFNDR-1 and PATHFNDR-2 studies

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company specializing in novel therapeutics for endocrine diseases, announced it wi

SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Crinetics Pharmaceuticals (CRNX) granted 102,350 stock options and 77,875 RSUs to 46 new employees under its 2021 Inducement Plan. The stock options hav

SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit ('RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the '2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Goldman Sachs has initiated coverage on Crinetics (CRNX) with a Neutral rating and set a price target of $36. The analyst, Richard Law, pointed out that the sto

Jane Street co-founder said to have been ‘duped’ into funding South Sudan coup. Jeff Bezos seeks more contracts for Blue Origin after Trump-Musk feud - report. Nvidia touches record high.

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company based in San Diego, announced on June 10, 2025, the granting of non-qualif

Summary Crinetics Pharmaceuticals Inc (CRNX), a clinical-stage pharmaceutical company specializing in endocrine disease therapeutics, announced on May 23, 2025,

Crinetics Pharmaceuticals (CRNX) to present at Jefferies Global Healthcare Conference 2025. Presentation scheduled for June 5, 2025, at 12:50 p.m. Easte

**media[635255]**

Crinetics Pharmaceuticals, indicated by the ticker CRNX, has been awarded orphan drug designation by the FDA for its drug candidate, paltusotine. This designati

New Analysis Shows Treatment with Investigational Paltusotine Resulted in Rapid and Durable IGF-1 Control in Surgically Naïve Acromegaly Patients Additional

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option

Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ETCompany ParticipantsGayathri Diwakar - Head-Investor...